Zenas BioPharma, Inc. Common Stock (ZBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.90B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Forecast
Analysts expect Zenas BioPharma, Inc. Common Stock (ZBIO) to earn -$5.62 per share in the fiscal year ending Dec 31, 2026, on revenue of $7.00M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 87.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 688.4%.
- Fiscal year ending Dec 31, 2026
- -$5.62
- EPS consensus, revenue $7.00M
- Fiscal year ending Dec 31, 2027
- -$4.82
- EPS consensus, revenue $55.19M
- Next report
- Mar 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.62 | -$5.62 to -$5.62 | 1 | $7.00M | $1.00M to $11.00M | 5 |
| Dec 31, 2027 | -$4.82 | -$5.11 to -$4.53 | 2 | $55.19M | $27.56M to $94.69M | 5 |
Quarterly Estimates
The EPS consensus falls from -$1.34 for the quarter ending Dec 31, 2026 to -$1.42 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.34 | -$1.34 to -$1.28 | 8 |
| Mar 31, 2027 | -$1.42 | -$1.45 to -$1.39 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.62 | -$5.62 | -$5.62 | -$5.62 | -$4.30 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.82 | -$4.66 | -$4.66 | -$4.66 | -$2.27 | N/A |
| Quarter ending Mar 31, 2027 | -$1.42 | -$1.37 | -$1.37 | -$1.37 | -$1.14 | N/A |
Frequently Asked Questions About ZBIO
What is the ZBIO stock forecast?
Consensus analyst estimates put Zenas BioPharma, Inc. Common Stock's EPS at -$5.62 for the fiscal year ending Dec 31, 2026, on revenue of $7.00M. The consensus rating from 8 analysts is Buy.
How do analysts rate ZBIO stock?
Of 8 analysts covering Zenas BioPharma, Inc. Common Stock, 0 rate it Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ZBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.62, with estimates from -$5.62 to -$5.62 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.82, with estimates from -$5.11 to -$4.53 from 2 analysts.
What revenue do analysts expect from Zenas BioPharma, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $7.00M, with estimates from $1.00M to $11.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $55.19M, with estimates from $27.56M to $94.69M.
How many analysts cover ZBIO?
8 analysts rate Zenas BioPharma, Inc. Common Stock stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
ZBIO pages: Overview, Earnings, Forecast, Financials, Competitors